Secondary Prevention for Atherosclerotic Cardiovascular Disease-PCSK9 Inhibitors, Prior Authorization, and Denial Appeal

PCSK9 Inhibitors, Prior Authorization, and Denial Appeal

Video Transcription

Video Summary

In this video, the speaker discusses various agents used for secondary prevention of cardiovascular events. They provide detailed information on each agent, including statins, ezetimibe, PCSK9 inhibitors (including evolocumab and alirocumab), inclisiran, and bempedoic acid. The speaker emphasizes the importance of working together with patients and referring physicians to optimize secondary prevention. They discuss lifestyle changes, risk factor modification, and the use of medication to control LDL levels. The speaker also provides information on the process of obtaining insurance coverage for expensive medications like PCSK9 inhibitors, including the use of prior authorization and appealing denials. They highlight the need to advocate for patients and utilize patient resources programs to ensure access to necessary medications. Finally, they briefly mention the use of fenofibrate to lower triglycerides when other measures fail.

Asset Subtitle

Debabrata Mukherjee, MD, FSCAI

Keywords

secondary prevention

PCSK9 inhibitors

insurance coverage

medication

fenofibrate